VANCOUVER, British Columbia, Aug. 13, 2018 (GLOBE NEWSWIRE) — BlissCo Cannabis Corp. (CSE: BLIS) (FRA: GQ4B), (“BlissCo”) or the (“Company”) is pleased to announce that it has earned an amendment to its ACMPR License from Health Canada to include the production of cannabis oil.
“Being only the 38th independent company to earn a cannabis oil production license is a testament to our team and the high standard that we hold our work to. This cannabis oil production license will allow us to continuously innovate and develop new cannabis products that our patients and adult use clients can enjoy healthily and confidently,” said Damian Kettlewell, CEO of BlissCo Cannabis Corp.
The amount of cannabis oil sold to medical patients in Canada has increased 91.7% throughout the past year.
BlissCo’s cannabis extraction lab is fully operational and features a MIDAS XII Co2 extraction system, which ensures that the team at BlissCo can focus on extracts that offer therapeutic terpenes with Full Spectrum oils, offering the Whole Plant approach to each patient.
“We intend to use these high-quality extractions to develop a diverse range of cannabis oil products including THC and CBD tinctures, capsules and sublingual sprays for the medical market,” added Kettlewell.
In line with BlissCo’s customer-oriented focus the company is planning to launch its licensed telemedicine smartphone app in October that will allow patients to obtain a verified prescription and order cannabis in an efficient, discrete and seamless manner.
BlissCo is building a strong company culture that is empowered to continuously innovate while remaining focused on compliance, this is demonstrated by the company’s track record meeting licensing and operational milestones. The team is currently working with regulators to earn its sales license amendment in an efficient manner.
“We are confident that our focus on medical cannabis revenue, digital sales solutions, value add products and international market development will deliver strong shareholder returns,” added Kettlewell.
About BlissCo Cannabis Corp.
BlissCo Cannabis Corp. (CSE: BLIS) (FRA: GQ4B) is an ACMPR licensed producer and future distributor of ultra-premium cannabis. The company sits at the heart of an international ecosystem and is focused on the success of its domestic and global partnerships.
BlissCo leverages the latest technology and is continuously developing its network of top-tier industry experts to drive the success of its brand and channels, moving premium Canadian cannabis to local and international markets.
BlissCo is backed by an experienced team that is deeply in tune and integrated with industry partners and BlissCo’s future patients and customers.
Learn more: BlissCo.com
On Behalf of the Board of Directors
BLISSCO CANNABIS CORP.
Damian Kettlewell, CEO, Founder & Chair
For further information please contact:
Ariel Jack Lewinski, Business Development & Investor Relations
This news release contains certain forward-looking information and forward-looking statements within the meaning of applicable securities legislation (collectively “forward-looking statements”). The use of any of the word “will” and similar expressions are intended to identify forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking statements. Such forward-looking statements should not be unduly relied upon. This news release contains forward-looking statements and assumptions pertaining to the following: the ability to execute on our strategic plans and the impact on our future operations, capital expenditures, receipt of a cannabis oil license and a license to sell dried cannabis and other objectives. Actual results achieved may vary from the information provided herein as a result of numerous known and unknown risks and uncertainties and other factors. The Company believes the expectations reflected in those forward-looking statements are reasonable, but no assurance can be given that these expectations will prove to be correct. The Company does not undertake to update these forward-looking statements, except as required by law.
The CSE has in no way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this press release.